Samer Gawrieh MD

Hepatology & Liver Transplantation

Professor of Medicine, Indiana University School of Medicine

550 University BlvdIndianapolis, IN 46202
Phone+1 317-944-5000
Fax+1 317-278-6870

Dr. Gawrieh is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gawrieh's full profile Already have an account?

Summary

Dr. Samer Gawrieh is a gastroenterologist based in Indianapolis, IN, with subspecialties in hepatology and liver transplantation. He completed his medical degree at the University of Aleppo Faculty of Medicine and pursued a residency in internal medicine at Cook County Health and Hospitals System, followed by gastroenterology and transplant hepatology fellowships at the Medical College of Wisconsin Affiliated Hospitals and Mayo Clinic College of Medicine and Science, respectively. His clinical expertise includes hepatology, liver cirrhosis, alcohol-associated liver disease, metabolic dysfunction-associated liver disease, and alcohol-associated hepatitis. Dr. Gawrieh has contributed to publications in hepatology, and actively participates in clinical trials related to liver diseases, including metabolic dysfunction-associated liver disease, and alcohol-associated hepatitis. He holds CMS Meaningful Use Stage 1 and 2 Certifications from Cerner Corporation for achievements in healthcare IT.

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Transplant Hepatology, 2004 - 2004
Medical College of Wisconsin Affiliated HospitalsFellowship, Gastroenterology, 2001 - 2004
Cook County Health and Hospitals SystemResidency, Internal Medicine, 1998 - 2001
University of Aleppo Faculty of MedicineClass of 1996

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

IN State Medical License 2013 - 2027
WI State Medical License 2001 - 2027
MN State Medical License 2003 - 2004
IL State Medical License 1998 - 2001
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Gastroenterology
American Board of Internal Medicine Transplant Hepatology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification Cerner Patient Portal and FirstNet, Cerner Corporation, 2013, 2015-2017
CMS Meaningful Use Stage 2 Certification FirstNet (CQM), Cerner Corporation, 2013, 2015-2017
CMS Meaningful Use Stage 1 Certification Cerner Patient Portal and Powerchart, Cerner Corporation, 2013, 2015-2017

Clinical Trials

Vitamin E for NASH Treatment in HIV Infected Individuals Start of enrollment: 2019 Oct 01
TERMINATED
PHASE2
Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis Start of enrollment: 2020 Jul 10
COMPLETED
PHASE2
Velacur by Sonic Incytes for Portal Hypertension Start of enrollment: 2021 Feb 01
COMPLETED
NA

Publications & Presentations

PubMed

A Bayesian Optimal Adaptive Clinical Trial Design for Sequentially Integrated Therapies.
Yining Li, Jiaying Guo, Samer Gawrieh, Wei Shen, Yong Zang
Statistics in Medicine. 2026-08-01
Short-Term Risk Stratification in Alcohol-Associated Hepatitis: Small HDL Particles and Inflammation Vulnerability Index Values Improve Model for End-Stage Liver Disease.
Eduardo Vilar-Gomez, Margery A Connelly, Vijay H Shah, Irina Shalaurova, Jill M Rafalko
Alcohol, Clinical & Experimental Research. 2026-08-01
SIRPα Cleavage Is Associated with Inflammatory Response, Corticosteroid Nonresponse, and Worse Prognosis in Clinical and Preclinical Models of Alcohol-Associated Hepat...
Ethan R Steele, Dylan Nunn, David Malicote, Tyler C Gripshover, Rui S Treves
The American Journal of Pathology. 2026-08-01

Press Mentions

Death from Liver Disease in Parents Linked to Elevated Hepatitis Risk in Children: Study Finds - VideoAugust 28th, 2025
Medical Bulletin 29/August/2025 - VideoAugust 28th, 2025
Parental History of Liver Disease More Than Doubles Risk of Alcohol-Associated Hepatitis in OffspringAugust 26th, 2025

Grant Support

Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD) - Indiana University Data Coordinating CenterINDIANA UNIVERSITY INDIANAPOLIS2018–2029